The recent surge in capital into boutique pharmaceutical companies, particularly those focusing on novel therapies and challenging drug development programs, has fueled what some are calling "High Stakeholder Pharma." https://jessebzxl647500.ourcodeblog.com/40565649/elite-investor-pharma-a-risky-bet